Tag: Delix Therapeutics - Psychedelic Alpha

Our 2022 Year in Review is now live.

Read more about the article Pioneering Delix Therapeutics Study Published in ‘Science’ Elucidates the Mechanism of Psychedelic-Induced Neuroplasticity

Pioneering Delix Therapeutics Study Published in ‘Science’ Elucidates the Mechanism of Psychedelic-Induced Neuroplasticity

Post published:February 16, 2023
Post category:Press Release

Read more about the article Delix Therapeutics Partners With Cellectricon, Expressive Neuroscience and Expands Science Team To Accelerate Drug Discovery and Translatability

Delix Therapeutics Partners With Cellectricon, Expressive Neuroscience and Expands Science Team To Accelerate Drug Discovery and Translatability

Post published:February 14, 2023
Post category:Press Release

Delix Therapeutics Expands World-Class Team with First Head of R&D

Post published:September 23, 2022
Post category:Press Release

Nature Biotechnology Selects Delix Therapeutics as a Leading Biotech Start-Up

Post published:September 13, 2022
Post category:Press Release

Read more about the article Delix Therapeutics Closes $30 Million Convertible Note Financing, Enters $10 Million Strategic Credit Facility Option in Partnership with Comerica Bank

Delix Therapeutics Closes $30 Million Convertible Note Financing, Enters $10 Million Strategic Credit Facility Option in Partnership with Comerica Bank

Post published:January 10, 2022
Post category:Press Release

End of content

No more pages to load

Psychedelic Alpha

Psychedelic Alpha is an independent newsletter and community that strives to empower a diverse constellation of individuals and organisations with the knowledge, network and nuance to make an impact within the field of psychedelic medicine and beyond

Quick Links

Insights and interviews delivered to your inbox. No spam, just valuable information.

Weekly Bulletin

Your weekly recap of news and analysis from the psychedelic sector.

Research Review

A monthly review of the most important psychedelics research.

News & Interviews

The latest news from across the psychedelics space.

Psychedelics Patent Trackers

We track the latest patents and filings related to psilocybin, MDMA and DMT.

Psychedelic Legalization & Decriminalization Tracker

Mapping psychedelic drug policy reform across the United States

Psychedelics Drug Development Tracker

From drug discovery to regulatory approval, we map drug development in psychedelics.

Stocks & Companies Directory

A directory of all the major psychedelics stocks, companies and ETFs.

Sector Landscape Map

Explore the Psychedelic Sector Landscape visually using our new tool.

Stock Watchlist

A one-stop overview of psychedelics stocks financial performance.

Pioneering Delix Therapeutics Study Published in ‘Science’ Elucidates the Mechanism of Psychedelic-Induced Neuroplasticity

Delix Therapeutics Partners With Cellectricon, Expressive Neuroscience and Expands Science Team To Accelerate Drug Discovery and Translatability

Delix Therapeutics Expands World-Class Team with First Head of R&D

Nature Biotechnology Selects Delix Therapeutics as a Leading Biotech Start-Up

Delix Therapeutics Closes $30 Million Convertible Note Financing, Enters $10 Million Strategic Credit Facility Option in Partnership with Comerica Bank

Psychedelic Alpha

Quick Links

Newsletter

Join Our Newsletter

Psychedelic sector insights, interviews and analysis delivered to your inbox.

No thanks, continue to site.